



PATENT APPLICATION
DOCKET NO.: 00537/18600

1653
TECH CENTER 1600/2900
TECH CENTER 1600/2900

RECEIVED
MAY 20 2002
RECEIVED
MAY 23 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P#10

Applicant(s): Zheng Xin Dong

Application No.: 09/857,636

Group Art Unit: Unknown

Filed: June 7, 2001

Examiner: Unknown

Title: ANALOGUES OF GLP-1

CERTIFICATE OF MAILING

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Date of Deposit: 5-13-2002

Alan Feeney
Alan Feeney

**INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO
CHARGE DEPOSIT ACCOUNT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)

☐ under 37 CFR 1.97(c) together with either:
☐ a Statement under 37 CFR 1.97(e), as checked below, or
☐ a \$240.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:
☐ a Statement under 37 CFR 1.97(e), as checked below, and
☐ a Petition under 37 CFR 1.97(d)(2), and
☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☐ Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.
(Filed after payment of issue fee)

☒ Some references were cited in a European Search Report in a counter part European application.

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449, with copies of the references noted thereon; with a Certificate of Mailing, or
- ☐ Copies of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ the enclosed English language abstracts.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO-1449 appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
- ☒ No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Assistant Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
- ☒ The Assistant Commissioner is hereby authorized to please charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,
BIOMEASURE, INCORPORATED


By 
Alan F. Feeney, Attorney for Applicant
Registration No.: 43,609
Telephone: (508) 478-0144
Facsimile: (508) 473-3531

Dated: 5/13/2002
27 Maple Street
Milford, Massachusetts 01757

PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
00537-186002APPLICATION NO.
09/857,636APPLICANT
Zheng Xin DongFILING DATE
June 7, 2001GROUP
Unknown

RECEIVED
 MAY 20 2002
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,545,618	Aug. 13, 96	Buckley et al.	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AB	WO 87/06941	19.11.87	PCT			
	AC	WO 91/11457	08.08.91	PCT			
	AD	0 658 568 A1	21.06.95	European			
	AE	0 699 686 A2 & A3	06.03.96	European			
	AF	0 708 179 A2 & A3	24.04.96	European			
	AG	0 733 644 A1	25.09.96	European			
	AH	WO 97/29180	14.8.97	PCT			
	AI	WO 98/03547	29.01.98	PCT			
	AJ	WO 98/08871	05.03.98	PCT			
	AK	WO 98/19698	14.05.98	PCT			
	AL	0 869 135 A1	07.10.98	European			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Ahren, Bo, et al.; "Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus"; 1997; Journal of Clinical Endocrinology and Metabolism; Vol.82:2; Pages 473-478
	AN	Deacon, C.F., et al.; "Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity"; 1998; Diabetologia; Vol. 41; Pages 271-278
	AO	Deacon, C.F., et al.; "Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig"; 1998; Diabetes; Vol. 47; Pages 764-769

EXAMINER

DATE CONSIDERED

RECEIVED
 MAY 23 2002
 TECH CENTER 1600/2900

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
00537-187002APPLICATION NO.
09/857,636APPLICANT
Zheng Xin DongFILING DATE
June 7, 2001GROUP
Unknown

FOREIGN PATENT DOCUMENTS


DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Gutniak, Mark, et al.; "Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus"; 1992; The New England Journal of Medicine; Vol. 326 No. 20; Pages 1316-1322
AQ	Mentlein, R., et al; "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, Glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum"; 1993; Biochem; Vol. 214; Pages 829-835
AR	Nauck, M.A., et al.; "Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM"; 1996; Diabetologia; Vol. 39:2; Pages 1546-1553
AS	Parker, J.C., et al.; "Structure-function analysis of a series of glucagon-like peptide-1 analogs"; 1998; Peptide Res; Vol. 11:5; Pages 398-409; XP-000788444
AT	Rachman, J., et al.; "Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM"; 1997; Diabetologia; Vol. 40; Pages 205-211
AU	Suzuki, S., et al.; "Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptides of Glucagon-Like Peptide-1 on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas"; 1989; Endocrinology; Vol. 125:6; Pages 3109-3114
AV	Thorens, Bernard, et al.; "Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM"; 1993; Diabetes; Vol. 42; Pages 1219-1225
AW	Thorens, Bernard, et al.; "Structure and Function of the Glucagon-Like Peptide-1 Receptor"; 1996; Handbook of Experimental Pharmacology; Vol. 123; Pages 255-273
AX	Todd, J.F., et al.; "Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus"; 1997; European Journal of Clinical Investigation; Vol. 27; Pages 533-536

EXAMINER

DATE CONSIDERED



RECEIVED
MAY 20 2002
TECH CENTER 1600/2900

RECEIVED
MAY 23 2002
TECH CENTER 1600/2900